This included all women with a family history of breast and/or ovarian cancer (190 individuals, 10 BRCA1 and 17 BRCA2 carriers, mutation prevalence 14.2%) and women diagnosed at 35 years or younger with no family history of breast and ovarian cancer (71 individuals, three BRCA1 and four BRCA2 carriers; mutation prevalence, 9.9% (Table 2)). This evidence concerns the gene BRCA2 and ovarian carcinoma.